Nicholas La Bella
About Nicholas La Bella
Nicholas La Bella is a seasoned pharmaceutical executive with over 40 years of experience in research and development, regulatory affairs, and clinical operations. He has held various leadership roles, including Chief Scientific Officer and Senior Vice President of Research and Development at ZyVersa Therapeutics Inc., and has successfully led pharmaceutical development programs resulting in NDA approvals.
Work at ZyVersa Therapeutics
Nicholas La Bella has been serving as Chief Scientific Officer and Senior Vice President of Research and Development at ZyVersa Therapeutics Inc. since 2014. In this role, he oversees the company's research initiatives and development strategies. His leadership contributes to the advancement of therapeutic programs within the organization, focusing on innovative solutions in the pharmaceutical sector. La Bella's extensive background in drug development and regulatory affairs supports ZyVersa's mission to bring new therapies to market.
Education and Expertise
Nicholas La Bella holds a Bachelor of Science in Pharmacy from the University of Connecticut, where he studied from 1973 to 1978. He furthered his education by obtaining a Master of Science in Drug Information and Communication from Long Island University, completing his studies from 1978 to 1981. His educational background provides a strong foundation for his over 40 years of experience in pharmaceutical research and development, regulatory affairs, and clinical operations.
Background
La Bella has held various significant positions in the pharmaceutical industry. He worked at Cardiokine as Vice President of Development from 2004 to 2009 and at PharmaNet Development Group, Inc. as Vice President of Operations in the Phase IV Division from 2001 to 2004. Additionally, he served as Chief Scientific Officer at Insmed, Inc. from 2010 to 2012. His management experience includes overseeing organizations with up to 250 individuals and participating in executive management teams.
Achievements
Throughout his career, Nicholas La Bella has successfully designed, developed, and executed pharmaceutical development programs across multiple therapeutic areas, leading to New Drug Application (NDA) approvals. His expertise encompasses proprietary and generic small molecule development, strategic assessments, and interactions with the FDA. He has also contributed to clinical studies in various phases and holds several publications and a patent for a pharmaceutical dosage form.